[{"orgOrder":0,"company":"MindMaze Therapeutics","sponsor":"Relief Therapeutics | NeuroX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Sapropterin Hydrochloride","moa":"Phenylalanine-4-hydroxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MindMaze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"MindMaze Therapeutics \/ Relief Therapeutics | NeuroX","highestDevelopmentStatusID":"10","companyTruncated":"MindMaze Therapeutics \/ Relief Therapeutics | NeuroX"}]

Find Clinical Drug Pipeline Developments & Deals by MindMaze Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Showcase
                          Not Confirmed
                          Biotech Showcase
                          Not Confirmed

                          Details : The proposed merger involves Sapropterin Dihydrochloride to target Phenylalanine-4-hydroxylase, addressing PHENYLKETONURIA.

                          Product Name : RLF-OD032

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 15, 2025

                          Lead Product(s) : Sapropterin Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Relief Therapeutics | NeuroX

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank